Genomic Characterization of Urothelial Carcinoma and Sarcomatoid Carcinoma of the Upper Urinary Tract
Cancers · 21.07.2026 · 18 (14) · 2352
DOI: 10.3390/cancers18142352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 21.07.2026. Verfasst von Salvador Jaime-Casas und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Sarcomatoid carcinoma of the upper urinary tract (SCUT) is a rare and aggressive malignancy. Due to its rarity, the molecular landscape and the prevalence of potentially targetable alterations are poorly characterized. We aimed to compare the clinical, pathological, and genomic profiles of SCUT and upper tract urothelial carcinoma (UTUC).
Methods
We leveraged the Tempus Lens clinically annotated genomic dataset to extract clinicopathologic and somatic genomic alteration data from patients with UTUC and SCUT. Patients with any-stage disease who underwent either blood- or tissue-based next-generation sequencing were included. Baseline clinical and demographic characteristics were summarized using descriptive statistics. Comparisons between groups were performed using Wilcoxon rank-sum test for continuous variables and the Chi-square test/Fisher’s exact test for categorical variables. Mutational frequencies and pairwise comparisons were performed to assess significant differences between groups.
Results
In total, 1721 patients were included, of which 1600 (93%) had UTUC and 121 (7%) had SCUT. Patients with SCUT were younger at diagnosis, 61 years (interquartile range (IQR) 54, 70), compared to UTUC, 71 years (IQR 64, 77) (p < 0.001), and were more likely to have node-positive disease at presentation (all p < 0.001). SCUT patients were more likely to show visceral metastases to the lung (44% vs. 21%), bone (31% vs. 17%), and brain (7% vs. 1%), compared to UTUC (all p < 0.05). Among SCUT patients, the most common genomic alterations were TERT (30%), TP53 (29%), NF2 (19%), PTEN (13%), SETD2 (12%), PBRM1 (12%), and BAP1 (8%). Among UTUC patients, the most common were TERT (52%), TP53 (52%), KMT2D (30%), FGFR3 (25%), ARID1A (20%), and KDM6A (18%). Compared to UTUC, SCUT was significantly enriched with NF2, SETD2, PBRM1, PTEN, and BAP1 (all p < 0.05). SCUT was depleted in FGFR3 (0% vs. 25%) and FGF4 (0% vs. 8%) mutations compared to UTUC (both p < 0.05). Targetable alterations were observed in SCUT, including NF2, SETD2, and PTEN.
Conclusion
Compared with UTUC, SCUT exhibits a more aggressive clinical and genomic phenotype, characterized by enrichment in NF2, SETD2, PBRM1, and PTEN. These findings underscore the divergent molecular landscape of SCUT and highlight potentially targetable genomic alterations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
- Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
- Instituto Nacional de Cancerologia (INCAN), Mexico City 14080, Mexico.
- M.D. Anderson Cancer Center, Houston, TX 77030, USA.
- Division of Urology and Urologic Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
ORCID-Profile: Miguel Zugman, Vitor Goes, George Zhang, Benjamin Mercier, Daniela V Castro, Alexander Chehrazi-Raffle, Tanya Dorff
Zitieren
APA
Jaime-Casas, S., Salgia, N. J., Zugman, M., Goes, V., Moradi, A., Shah, K., Winayak, R., Barragan-Carrillo, R., Fann, J., Zhang, G., Mercier, B., Castro, D. V., Dizman, N., Hsu, J., Chehrazi-Raffle, A., Dorff, T., Yip, W., Pal, S. K., & Tripathi, A. (2026). Genomic Characterization of Urothelial Carcinoma and Sarcomatoid Carcinoma of the Upper Urinary Tract. Cancers, 18(14), 2352. https://doi.org/10.3390/cancers18142352
Vancouver
Jaime-Casas S, Salgia NJ, Zugman M, Goes V, Moradi A, Shah K, et al. Genomic Characterization of Urothelial Carcinoma and Sarcomatoid Carcinoma of the Upper Urinary Tract. Cancers. 2026;18(14):2352. doi:10.3390/cancers18142352
BibTeX
@article{JaimeCasas2026,
author = {Jaime-Casas, Salvador and Salgia, Nicholas J and Zugman, Miguel and Goes, Vitor and Moradi, Ali and Shah, Koral and Winayak, Rahul and Barragan-Carrillo, Regina and Fann, Jadon and Zhang, George and Mercier, Benjamin and Castro, Daniela V and Dizman, Nazli and Hsu, JoAnn and Chehrazi-Raffle, Alexander and Dorff, Tanya and Yip, Wesley and Pal, Sumanta K and Tripathi, Abhishek},
title = {Genomic Characterization of Urothelial Carcinoma and Sarcomatoid Carcinoma of the Upper Urinary Tract},
journal = {Cancers},
year = {2026},
volume = {18},
number = {14},
pages = {2352},
doi = {10.3390/cancers18142352}
}
EUVIMED